Omeza LLC

Jun 12, 2024

Case Studies of Patients with Diabetic Foot Ulcers Showed 90 to 100 Percent Wound Closure at 12 weeks Following Weekly Treatment with Novel OMEZA® OCM(TM)

Jun 06, 2024

OMEZA® CLINICAL STUDY TO EVALUATE OCM(TM) WOUND MATRIX FOR THE TREATMENT OF CHRONIC CUTANEOUS WOUNDS/ULCERS OF MULTIPLE ETIOLOGIES HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS WILL BE SUBMITTED TO A PEER REVIEW JOURNAL.

Jun 05, 2024

NOVEL OMEZA® OCM(TM) WOUND MATRIX CLINICAL STUDY IN VENOUS LEG ULCERS HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS TO BE SUBMITTED TO PEER REVIEW JOURNAL

May 20, 2024

POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCM(TM) AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PSEUDOMONAS AERUGINOSA (PA) IN PORCINE WOUND MODEL

May 14, 2024

NOVEL OMEZA® OCM(TM) WOUND MATRIX DEMONSTRATES MULTI-MODAL EFFECTS BY REDUCING BACTERIAL CONTAMINATION IN "STALLED", HARD TO TREAT WOUNDS, WHILE SUPPORTING HEALING RATES

May 03, 2024

NOVEL OMEZA® OCM(TM) WOUND HEALING PLATFORM COMBINED WITH OFFLOADING IN PATIENTS WITH DIABETIC FOOT ULCERS DEMONSTRATED DRAMATIC HEALING RATES WITHIN 12 WEEKS OR LESS

Mar 14, 2024

Positive Results from Diabetic Foot Ulcer Clinical Trial Show Dramatic Healing Rate within 12 Weeks or Less Using Novel Omeza® Platform and Offloading